Global Vaccine CDMO Market Report Segmented by Vaccine Type (mRNA, Viral Vector, Recombinant Protein, DNA Vaccine), Phase (Pre-clinical, Clinical, Commercial), End User (Biopharmaceutical & Vaccine Developers) Forecasts to 2030
The global vaccine CDMO market is set to witness a growth rate of 8% in the next 5 years. Increasing demand for vaccines, rising biopharma and government partnerships with CDMOs, advancements in vaccine manufacturing technologies, growing need for specialized CDMO services for new vaccine technologies, increasing private and public investments in vaccine CDMOs, and increasing outsourcing trend to reduce costs and accelerate time-to-market are some of the key factors driving the vaccine CDMO market. To learn more about the research report, download a sample report.
Report Overview
A vaccine contract development and manufacturing organization (CDMO) provides outsourced services for the development, manufacturing, and commercialization of vaccines. These organizations support pharmaceutical and biotech companies by offering end-to-end solutions, including process development, drug substance production, fill-finish, packaging, and regulatory compliance. Vaccine CDMOs specialize in advanced platforms such as mRNA, viral vectors, recombinant proteins, and inactivated vaccines, helping clients scale up production efficiently. They play a critical role in accelerating vaccine development, particularly during pandemics, by offering flexible, high-capacity manufacturing.
To learn more about this report, download the PDF brochure
Increasing demand for vaccines to propel market demand
The rising demand for vaccines, driven by infectious disease outbreaks, expanding immunization programs, and mRNA vaccine advancements, is accelerating growth in the vaccine CDMO market. Biopharma companies increasingly outsource manufacturing to CDMOs to scale production, reduce costs, and meet stringent regulatory requirements. The success of COVID-19 mRNA vaccines has fueled demand for CDMOs specializing in lipid nanoparticle (LNP) formulation and cold chain logistics. Additionally, global vaccine initiatives and government partnerships are securing long-term contracts for CDMOs. This trend is pushing major players to expand manufacturing capacities to meet growing vaccine needs worldwide.
Advancements in vaccine manufacturing technologies are driving the market growth
Advancements in vaccine manufacturing technologies, such as mRNA, viral vectors, cell-based production, and single-use bioreactors, are driving the Vaccine CDMO market. These innovations require specialized expertise and infrastructure, prompting biopharma companies to outsource production to CDMOs with advanced capabilities. mRNA vaccine breakthroughs, particularly in LNP formulation and enzymatic synthesis, have increased demand for CDMO services. Additionally, automation, continuous manufacturing, and AI-driven process optimization are enhancing production efficiency. Leading CDMOs are focusing on next-generation vaccine development, accelerating global vaccine availability and commercialization.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global vaccine CDMO market is marked by the presence of established and emerging market players such as Lonza Group, Thermo Fisher Scientific, Catalent, Inc, Samsung Biologics, CordenPharma, WuXi Vaccines, Recipharm AB, ICON plc, FUJIFILM Diosynth Biotechnologies, and Curia Global, Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth Rate | 8% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Vaccine Type, Phase, End User |
| Regional Scope |
|
| Key Companies Mapped | Lonza Group, Thermo Fisher Scientific, Catalent, Inc, Samsung Biologics, CordenPharma, WuXi Vaccines, Recipharm AB, ICON plc, FUJIFILM Diosynth Biotechnologies, and Curia Global, Inc.; among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Vaccine CDMO Market Segmentation
This report by Medi-Tech Insights provides the size of the global vaccine CDMO market at the regional- and country-level from 2023 to 2030. The report further segments the market based on vaccine type, phase, end user.
Market Size & Forecast (2023-2030), By Vaccine Type, USD Million
- mRNA Vaccines
- Viral Vector Vaccines
- Recombinant Protein Vaccines
- Inactivated & Live-Attenuated Vaccines
- Conjugate & Toxoid Vaccines
- DNA Vaccines
- Others
Market Size & Forecast (2023-2030), By Phase, USD Million
- Pre-clinical
- Clinical
- Commercial
Market Size & Forecast (2023-2030), By End User, USD Million
- Biopharmaceutical & Vaccine Developers
- Government & Public Health Agencies
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the vaccine CDMO market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the vaccine CDMO market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Vaccine CDMO Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Increasing demand for vaccines
- Rising biopharma and government partnerships with CDMOs
- Advancements in vaccine manufacturing technologies
- Growing need for specialized CDMO services for new vaccine technologies
- Increasing private and public investments in vaccine CDMOs
- Increasing outsourcing trend to reduce costs and accelerate time-to-market
- Restraints
- High initial capital investment
- Complex regulatory environment
- Supply chain and raw material shortages
- Opportunities
- Expansion of mRNA and LNP-based vaccine CDMO services
- Growing outsourcing trend in biopharma
- Rising demand for personalized vaccines
- Emerging markets as vaccine manufacturing hubs
- Key Market Trends
- Growing adoption of viral vector and cell-based vaccine platforms
- Expansion of modular and single-use manufacturing technologies
- Expansion of fill-finish capabilities
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Vaccine CDMO Market Size & Forecast (2023-2030), By Vaccine Type, USD Million
- Introduction
- mRNA Vaccines
- Viral Vector Vaccines
- Recombinant Protein Vaccines
- Inactivated & Live-Attenuated Vaccines
- Conjugate & Toxoid Vaccines
- DNA Vaccines
- Others
- Global Vaccine CDMO Market Size & Forecast (2023-2030), By Phase, USD Million
- Introduction
- Pre-clinical
- Clinical
- Commercial
- Global Vaccine CDMO Market Size & Forecast (2023-2030), By End User, USD Million
- Introduction
- Biopharmaceutical & Vaccine Developers
- Government & Public Health Agencies
- Others
- Global Vaccine CDMO Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Vaccine CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Canada
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- US
- Europe Vaccine CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Germany
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- France
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Italy
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Spain
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Rest of Europe
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- UK
- Asia Pacific (APAC) Vaccine CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Japan
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- India
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- China
- Latin America (LATAM) Vaccine CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Middle East & Africa (MEA) Vaccine CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Vaccine Type (USD Million)
- Market Size & Forecast, By Phase (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Service Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Lonza Group
- Thermo Fisher Scientific
- Catalent, Inc
- Samsung Biologics
- CordenPharma
- WuXi Vaccines
- Recipharm AB
- ICON plc
- FUJIFILM Diosynth Biotechnologies
- Curia Global, Inc.
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Biopharmaceutical & Vaccine Developers; Government & Public Health Agenciesand Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
